Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precise Design CAR-T
- Development stage
- Phase 1
- Lead developer
- Ruijin Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Precise Design CAR-T refers to an investigational chimeric antigen receptor T-cell (CAR-T) therapy program developed by Ruijin Hospital (Shanghai Jiao Tong University School of Medicine) for the treatment of relapsed or refractory hematologic malignancies. The "Precise Design" approach utilizes a personalized strategy where CAR-T cells are engineered to target specific antigens—most commonly CD19, CD22, or BCMA—based on the individual patient's tumor antigen expression profile. The therapy involves the ex vivo genetic modification of autologous or allogeneic T cells to express a chimeric receptor that facilitates the recognition and lysis of malignant cells. This program is currently being evaluated in clinical trials to optimize efficacy and safety by matching the CAR-T construct to the specific biological characteristics of the patient's disease.
- Other names
- Precise Design of Cell TherapyRuijin Hospital CAR-T therapyPrecise Design CAR-T-Ruijin Hospital-hematologic malignancy
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on Precise Design CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precise Design CAR-T.